A Study of the Safety, Engraftment, and Action of Multi-Dosed NB01 in Adults With Moderate Acne

Acne Vulgaris Clinical Trial

Official title:

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase 1B Study of the Safety, Short-Term Engraftment and Action of NB01 in Adults With Moderate Acne

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03709654
• Other study ID #: NB01-P1BMA
• Status: Completed
• Phase: Phase 1
• Start date: November 1, 2018
• Est. completion date: September 30, 2019

Study information

• Verified date: July 2020
• Source: Naked Biome, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Acne vulgaris is a disease caused my multiple factors including overgrowth of bacteria, clogged pores, excessive sebum production and hormonal changes. Recent literature from the Human Microbiome Project has shown there are bacterial strains specific to healthy and acne disease states (Fitz-Gibbon et al, 2013, Johnson et al, 2016, McDowell et al, 2012, Tomida et al, 2013)

From this data, the investigators hypothesize that by eliminating disease-associated bacterial strains and replacing them with health-associated strains, recurrences or flares of acne may be improved, mitigated, and prevented. Instead of current approaches which focus on eliminating all bacteria from the skin, the investigators aim to deliver healthy bacteria to restore the skin to a healthy state via this replacement therapy.

The investigators aim to test this in a Phase Ib multiple application study evaluating the safety, tolerability, and clinical impact that a multiple applications of NB01 have on adult subjects with moderate acne.

Description:

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase 1B Study of the Safety, Short-Term Engraftment and Action of NB01 in Adults With Moderate Acne

Acne vulgaris is a multifactorial disease caused by overgrowth of Propionibacterium acnes (P. acnes), impaction of hair follicles, excessive sebum production and hormonal dysregulation. Recent literature from the Human Microbiome Project has shown there are unique microbial signatures specific to healthy and acne disease states.

From this data, the investigators hypothesize that by eliminating resident disease-associated bacterial strains and replacing them with health-associated strains, recurrences/fares of acne may be improved, mitigated, and prevented. Instead of current approaches which focus on eliminating all bacteria from the skin, the investigators aim to deliver healthy bacteria (NB01) to restore the skin to a healthy state via this replacement therapy.

The investigators aim to test this in a Phase 1B multiple application study evaluating the safety, tolerability, and clinical impact that a multiple, daily, applications of NB01 has on adult subjects with moderate acne. Investigators will be profiling the change in microbiome over the course of therapy to determine if exogenously delivered bacteria can populate the skin (engraftment) and cause a shift in the microbiome safely and subsequently impact acne biomarkers that may correlate with clinical disease.

The investigators intend for this therapy to eventually be used in acne subjects with ages ranging from 13-40, and all disease severities as either monotherapy for mild to mild/moderate acne and as an adjuvant therapy for moderate to severe acne at all body sites, with special attention to facial involvement.

This approach is standard to acne therapy whereby mild disease will be treated with a monotherapy (i.e., topical Benzoyl peroxide [BPO]) and moderate/severe disease will be treated with various combinatory regimens (topical antibiotics, BPO, topical retinoids, oral antibiotics).

Primary Objectives:

1. To determine the safety and tolerability of a multiple application of topical P. acnes microbiome transplant ("NB01").

Exploratory Objectives:

1. To define engraftment duration of NB01.

2. To evaluate preliminary clinical efficacy using Acne Lesion Counts (total, inflammatory, and non-inflammatory), Investigator Global Assessment (IGA), and subjective improvement of acne based on subject reported outcomes (Acne QoL Questionnaire).

3. To evaluate treatment effects, based on sebum production in a subpopulation from sites 02 and 03.

Approximately 36 total male and female adult subjects combined with moderate, non-cyclical acne will be enrolled into the trial. Approximately twenty four (24) subjects will be randomly assigned treatment and twelve (12) subjects will be randomly assigned to vehicle control.

This is a multiple topical application study of live bacteria for the study of acne in adult subjects. Following a 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial, 11 weeks of daily topical application of NB01 will be evaluated.

Subject participation in the trial will approximately 12 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: September 30, 2019
• Est. primary completion date: September 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Subject has provided written informed consent.

2. Subject is male or non-pregnant female, 18-40 years of age, inclusive at Screening.

3. Subject has moderate facial acne vulgaris

4. Female subject with non-cyclical acne.

5. Women of childbearing potential (WOCBP) willing to use adequate contraception during study participation

6. Male subjects willing to use an acceptable method of contraception during study participation.

7. Subject has the ability to personally apply benzoyl peroxide (BPO) and study drug, as per protocol.

Exclusion Criteria:

1. Subject has active bacterial, viral, or fungal skin infections.

2. Subject has active nodulocystic acne or acne conglobate, acne fulminans, or other forms of acne (e.g., acne mechanica).

3. Subject is currently participating in an investigational drug, device, or biologic study or has used an investigational drug, biologic or device treatment within 30 days prior to first application of the study drug.

4. Subjects with prosthetic heart valves, pacemakers, intravascular catheters, or other foreign or prosthetic devices/implantable devices/hardware.

5. Subject has a history of chronic human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) infections.

6. Subject has a history of malignancy (with the exception of non-melanoma skin cancer).

7. Subject is immunosuppressed (such as resulting from transplantation, immunosuppressive therapy, active HIV infection/acquired immune deficiency syndrome [AIDS], neutropenia).

8. Subject had a major surgical procedure, open biopsy, or significant traumatic injury within 14 days of initiating study drug (unless the wound has healed), or anticipation of the need for major surgery during the study.

9. Subjects with close contacts (e.g., spouses, children, or members in the same household) that have severe skin barrier defects or are immunocompromised.

10. Female subject is pregnant or lactating or is planning to become pregnant and/or breast feed within the duration of study participation.

Other entry criteria not listed above will be reviewed of each prospective subject by the study staff to confirm eligibility

Related Conditions & MeSH terms

• Acne Vulgaris

Intervention

Biological:
• NB01
5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01

Other:
• Vehicle Control
5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control

Locations

Country	Name	City	State
United States	01	Arlington	Texas
United States	02	Austin	Texas
United States	03	San Diego	California

Sponsors (2)

Lead Sponsor	Collaborator
Naked Biome, Inc.	Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (4)

Fitz-Gibbon S, Tomida S, Chiu BH, Nguyen L, Du C, Liu M, Elashoff D, Erfe MC, Loncaric A, Kim J, Modlin RL, Miller JF, Sodergren E, Craft N, Weinstock GM, Li H. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. — View Citation

Johnson T, Kang D, Barnard E, Li H. Strain-Level Differences in Porphyrin Production and Regulation in Propionibacterium acnes Elucidate Disease Associations. mSphere. 2016 Feb 10;1(1). pii: e00023-15. doi: 10.1128/mSphere.00023-15. eCollection 2016 Jan-F — View Citation

McDowell A, Barnard E, Nagy I, Gao A, Tomida S, Li H, Eady A, Cove J, Nord CE, Patrick S. An expanded multilocus sequence typing scheme for propionibacterium acnes: investigation of 'pathogenic', 'commensal' and antibiotic resistant strains. PLoS One. 201 — View Citation

Tomida S, Nguyen L, Chiu BH, Liu J, Sodergren E, Weinstock GM, Li H. Pan-genome and comparative genome analyses of propionibacterium acnes reveal its genomic diversity in the healthy and diseased human skin microbiome. mBio. 2013 Apr 30;4(3):e00003-13. do — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Changes in Local Skin Reactions	Local Skin Reactions (LSRs) including Erythema, edema, erosion/ulceration, scaling/dryness, and scabbing/crusting scored at Baseline (day of first application) and Week 12 (end of treatment) and reported for each visit as: Absent, Mild, Moderate, or Severe.; The number of participants (and %) with no change or improvement from Baseline to week 12 visit are reported.; The number of participants (and %) whose score worsened from Baseline to week 12 visit are reported.	Day 0 through day 80
Primary	Number of Participants With Successful Follicular Engraftment of NB01	Follicular engraftment sampling used Biore® Strips at Screening and day 80 (several days after end of treatment).; The number of subjects with "success" at EOT where "success" is defined as a Follicular Biore® sample with "yes" outcome based on recovery of live NB01at day 80.	12 weeks
Primary	Absolute Change in Genotype Markers: Skin Surface Engraftment "Success"	Skin surface engraftment "success" endpoint is de?ned by a change in genotype (TaqMan) markers compared to Screening; value is percentage of bacterial population containing health-associated genotype. Result is absolute change from screening value.	Day 0 through day 80
Primary	Absolute Change From Screening in Acne Lesion Counts	Reporting absolute change in counts.	Day 0 through day 80
Primary	Percent Change From Screening in Acne Lesion Counts	Efficacy endpoint: Percent change from Screening lesion counts at Day 80 (end of treatment)	Day 0 through day 80
Primary	Number of Participants Achieving "Success" on Investigator Global Assessment (IGA)	The investigator assessed the participant's inflammatory lesions on the face using the Investigator Global Assessment (IGA) 5-point scale.; The scale ranges from 0 (best): clear, no evidence of papules or pustules to 4 (worst): severe, inflammatory lesions are more apparent, many papules/pustules.; The outcome is the number of subjects in each treatment group achieving "success" at Week 12; "success" defined as an IGA score of "clear (score=0)" or "almost clear (score=1)" and at least a two-point reduction in IGA compared to Baseline.	Day 0 through day 80
Primary	Change in Acne QoL Questionnaire Score	At each visit, subjects were asked to complete the Acne Quality of Life [QoL] Questionnaire to assess subjective improvement of acne with 7 response choices ranging from extremely to not at all. The total score ranges from 19 to 114; higher scores reflect improved QoL.; Outcome measure is absolute change in Acne QoL (Total Score) from Baseline to Day 80.	Day 0 through day 80
Primary	Absolute Change From Screening in Acne Lesion Counts: Outlier Censored	After reviewing the data, one Treatment Arm subject was found to be an extreme outlier and was censored from this ad-hoc analysis.; Reporting absolute change in counts.	Day 0 through day 80
Primary	Percent Change From Screening in Acne Lesion Counts: Outlier Censored	Efficacy endpoint: Percent change from Screening lesion counts at Day 80 (end of treatment)	Day 0 through day 80
Primary	Follicular Engraftment	Follicular communities were genotyped for health-associated loci at both Screening and 12-week visits. The percent increase of Cas5 in multiple communities from each subject is reported.	12 weeks
Secondary	Absolute Change in Sebum Production.	Exploratory Endpoint: Absolute change from Baseline to week 12 in sebum production measured at the mid-glabellar region of the forehead using a Sebumeter.	Day 0 through day 80

External Links

•   [FDA] Guidance for Industry: Acne Vulgaris: Developing Drugs for Treatment. Draft: September 2005
•   DermNet New Zealand. Acne vulgaris: Acne Grading
•   Early Clinical Trials with Live Biotherapeutic FDA Guidance for Industry: Products: Chemistry, Manufacturing, and Control Information
•   FDA Guidance for Industry CGMP for Phase 1 Investigational Drugs